10x Genomics (TXG) Current Deferred Revenue (2018 - 2026)
10x Genomics' Current Deferred Revenue history spans 8 years, with the latest figure at $23.9 million for Q4 2025.
- On a quarterly basis, Current Deferred Revenue fell 27.94% to $23.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.9 million, a 27.94% decrease, with the full-year FY2025 number at $23.9 million, down 27.94% from a year prior.
- Current Deferred Revenue hit $23.9 million in Q4 2025 for 10x Genomics, down from $33.0 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for TXG hit a ceiling of $33.5 million in Q1 2025 and a floor of $4.5 million in Q1 2021.
- Historically, Current Deferred Revenue has averaged $16.0 million across 5 years, with a median of $12.7 million in 2022.
- Biggest five-year swings in Current Deferred Revenue: soared 165.57% in 2023 and later dropped 27.94% in 2025.
- Tracing TXG's Current Deferred Revenue over 5 years: stood at $7.7 million in 2021, then soared by 43.5% to $11.0 million in 2022, then surged by 99.09% to $22.0 million in 2023, then surged by 51.02% to $33.2 million in 2024, then decreased by 27.94% to $23.9 million in 2025.
- Business Quant data shows Current Deferred Revenue for TXG at $23.9 million in Q4 2025, $33.0 million in Q3 2025, and $21.4 million in Q2 2025.